Emergent BioSolutions Inc/ US29089Q1058 /
2024-04-18 9:59:55 PM | Chg. -0.04 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
1.87USD | -2.09% | 17,426 Turnover: 33,041.44 |
-Bid Size: - | -Ask Size: - | 97.1 mill.USD | - | - |
Assets
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 510.2000 | 542.3000 | 644.1000 | 800.1000 | 817.6000 | ||||||
Intangible Assets | 761.6000 | 712.9000 | 663.1000 | 604.6000 | 728.8000 | ||||||
Long-Term Investments | - | - | - | - | - | ||||||
Fixed Assets | 1,608.6000 | 1,641.1000 | 1,687.3000 | 1,686.9000 | - | ||||||
Inventories | 205.8000 | 222.5000 | 307 | 350.8000 | 350.7000 | ||||||
Accounts Receivable | 262.5000 | 270.7000 | 230.9000 | 274.7000 | 159.2000 | ||||||
Cash and Cash Equivalents | 112.2000 | 167.8000 | 621.3000 | 576.1000 | 642.6000 | ||||||
Current Assets | 620.8000 | 686.2000 | 1,195.9000 | 1,272.1000 | 1,210.4000 | ||||||
Total Assets | 2,229.4000 | 2,327.3000 | 2,883.2000 | 2,959 | 3,166.3000 |
Liabilities
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 80.7000 | 94.8000 | 136.1000 | 128.9000 | 103.5000 | ||||||
Long-term debt | 784.5000 | 798.4000 | 841 | 809.4000 | 448.5000 | ||||||
Liabilities to Banks | - | - | - | - | - | ||||||
Provisions | 72 | 63.9000 | 53.2000 | - | - | ||||||
Liabilities | 1,218.5000 | 1,238.8000 | 1,436.2000 | 1,340 | 1,778.6000 | ||||||
Share Capital | - | - | - | - | - | ||||||
Total Equity | 1,010.9000 | 1,088.5000 | 1,447 | 1,619 | 1,387.7000 | ||||||
Minority Interests | - | - | - | - | - | ||||||
Total liabilities equity | 2,229.4000 | 2,327.3000 | 2,883.2000 | 2,959 | 3,166.3000 |
Income Statement
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 782.4000 | 1,106 | 1,555.4000 | 1,792.7000 | 1,117.5000 | ||||||
Depreciation (total) | 25 | 58.7000 | 59.8000 | 58.5000 | 59.9000 | ||||||
Operating Result | 89.8000 | 114.1000 | 433.8000 | 352.6000 | -170 | ||||||
Interest Income | -9.9000 | -38.4000 | -31.3000 | -34.5000 | -37.3000 | ||||||
Income Before Taxes | 81.5000 | 77.4000 | 407.2000 | 314.4000 | -219 | ||||||
Income Taxes | 18.8000 | 22.9000 | 102.1000 | 83.5000 | -7.4000 | ||||||
Minority Interests Profit | - | - | - | - | - | ||||||
Net Income | 62.7000 | 54.5000 | 305.1000 | 230.9000 | -211.6000 |
Per Share
Cash Flow
2018 US GAAP in mill. USD |
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 41.8000 | 188 | 536 | 321.1000 | -34.1000 | ||||||
Cash Flow from Investing Activities | -897.2000 | -96.9000 | -151 | -225 | -381.3000 | ||||||
Cash Flow from Financing | 788.7000 | -35.9000 | 69.5000 | -141 | 481.2000 | ||||||
Decrease / Increase in Cash | -66.9000 | 55.6000 | 453.5000 | -45.2000 | 66.3000 | ||||||
Employees | 1,705 | 1,834 | 2,200 | - | - |